← Back to Search

Organ Preservation Device

OCS Heart System for Heart Transplant

N/A
Waitlist Available
Research Sponsored by TransMedics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 and 12 months
Awards & highlights

Study Summary

This study is evaluating whether a device which keeps hearts alive outside of the body may help improve the number of organs available for transplant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Absence of severe PGD
Secondary outcome measures
Donor heart utilization rate
Incidence of severe PGD
Other outcome measures
Hospital stay
ICU stay
Incidence of primary graft failure
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: OCS PreservationExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OCS Heart System
2019
N/A
~260

Find a Location

Who is running the clinical trial?

TransMedicsLead Sponsor
22 Previous Clinical Trials
18,496 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Heart EXPAND Continued Access Protocol
2019. "Heart EXPAND Continued Access Protocol". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03835754.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top